NCT Number: NCT01722435
Completion of OST - a Prospective Study
Only limited information on the process of completing long-term opiate substitution treatment (OST) with substances like methadone exist. Furthermore, systematic knowledge from scientific studies is scarce, there are only few studies with respect to treatment completion or regular termination (mainly catamnestic analyses). Studies by Nordt et al. (2004) or Nordt & Stohler (2006) show an estimated rate of 10% of patients per year who terminate OST by means of tapering the substitution agent or changing into withdrawal treatment in specialized clinics. It is state of the art that an indication for termination of OST has to be based on a common agreement between the patient and the doctor. Furthermore, the patient should live in a stable social situation and the state of health had markedly improved. Finally, the patient has to be free of (illegal) drug use for at least 6 months and the individual aims of treatment should have been reached (Vader et al. 2003).
The main objective of the prospective and explorative study is the systematic description of the process of termination of OST. With a comparison between patients who complete OST regularly and patients who terminate treatment prematurely (or are still in treatment) predictors of positive termination of OST can be identified.
Patients treated with methadone or levomethadone of 5 general practitioners' practices and 2 specialized clinics who might be able to terminate OST during the next 12 months from the doctors' perspective can take part in the study. In addition to baseline examination further assessments take place every 3 months (i.e. after 3, 6, 9 and 12 months). The questionnaires include state of health, well-being, social situation as well as drug and alcohol use. Furthermore, the treating doctors are asked every 3 months to fill out questionnaires on infections and other disorders, clinical characteristics, dosage process and drug use (measured by urine samples).
Patients who will be successful in completing OST during the observational period will be compared with the remaining cases.
Finally, a 6-month follow-up is planned in order to investigate the stability and maintenance of the situation at month 12.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- opioid dependence according ICD-10
- Minimum age of 18 years
- In OST with methadone or levomethadone
- Expected or planned treatment completion during the next 12 months
- Informed consent to participate in the study
Exclusion criteria
- Patients with planned hospitalisation during the next 12 months
- Patients who are likely or it is save to assume that they will be incarcerated or imprisoned during the next 12 months
- Disability to take part in the study or follow the study conditions
Treatment and study plan
Primary outcomes
-
Completion of OST
Time frame: 18 months
Regularly completion of OST, i.e. not being on opioid medication any more, during the study period.
-
OST Drop-outs
Time frame: 18 months
Participants dropped out of OST Treatment during the study period.
Secondary outcomes
-
Mean Time to Complete OST
Time frame: 18 months
Mean time of study participation (M, SD) until Treatment completion or end of study (after 18 months).
-
Mean Time to Drop-out of OST
Time frame: 18 months
Mean time of study participation (M, SD) until drop-out of treatment.
-
Mean Time Staying in OST
Time frame: 18 months
Mean time of study participation (M, SD) of patients who stayed in OST Treatment until end of study (after 18 months).
Sponsors and collaborators
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Other
Collaborators
- Asklepios Kliniken Hamburg GmbH
- Dr. Jochen Brack
- Dr. Rainer Ullmann
- Dr. Sibylle Quellhorst
- Gesine Hoeft
- Michael Klemperer
Registry information
Official study title
Completion of Substitution Treatment With Methadone/Levomethadone - a Prospective Study
Important dates
- Study start
- 2011
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Nov 6, 2012
- Registry last updated
- Oct 9, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Innovative Intervention for OUD Treatment
NCT04325659
Chemically-Induced Disorders, Mental Disorders
Baltimore, Maryland, United States
View Trial DetailsUtilizing Helpline for Opioid Dependence Treatment
NCT03969238
Agnosia, Chemically-Induced Disorders
Charlottesville, Virginia, United States
View Trial DetailsIntervening With Opioid-Dependent MothersMothers and Infants
NCT04454645
Chemically-Induced Disorders, Infant Development
Newark, Delaware, United States
View Trial DetailsAddiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
NCT03089983
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
Kajang, Selangor, Malaysia
View Trial Details